More children die of brain tumors than any other type of cancer. Diffuse midline gliomas (DMGs) are a particularly deadly kind, and are difficult to treat with drugs or surgery because they're in an important part of the ...
Feb 4, 2022
0
131
A comprehensive study—conducted by researchers at Sanford Burnham Prebys, the National Cancer Institute (NCI) and other groups—has shown that gene editing, specifically gene knockout (KO), with CRISPR -Cas9 can favor ...
Nov 11, 2021
0
80
The tumor suppressor protein p53 is mutated in more than half of all human cancers. Several drugs that potentially can restore mutant p53 to its normal cancer-killing function are in clinical investigation.
Aug 31, 2021
0
108
Scientists at VCU Massey Cancer Center have identified a protein that operates in tandem with a specific genetic mutation to spur lung cancer growth and could serve as a therapeutic target to treat the disease.
Apr 19, 2021
0
137
Scientists at Sanford Burnham Prebys have discovered that combining immunotherapy with a drug called tumor necrosis factor (TNF) eradicated a deadly type of pediatric brain tumor in mice. The discovery, published in Nature ...
May 18, 2020
0
222
Regenerative medicine using human pluripotent stem cells to grow transplantable tissue outside the body carries the promise to treat a range of intractable disorders, such as diabetes and Parkinson's disease.
Apr 26, 2017
0
23
For a small percentage of cancer patients, treatment aimed at curing the disease leads to a form of leukemia with a poor prognosis. Conventional thinking goes that chemotherapy and radiation therapy induce a barrage of damaging ...
Dec 8, 2014
0
0
(Medical Xpress) -- Mutations to a gene called p53 have been linked to half of all cancers, leading to tumor growth and the spread of cancerous cells. Now, a Cornell-led study identifies for the first time the mechanisms ...
Aug 24, 2011
0
0
Oncogenes are generally thought to be genes that, when mutated, change healthy cells into cancerous tumor cells. Scientists at the Keck School of Medicine of the University of Southern California (USC) have proven that those ...
Jul 18, 2011
1
0
A new editorial perspective titled "Genetic modifiers of p53: opportunities for breast cancer therapies" has been published in Oncotarget.
Oct 25, 2023
0
0
